Adlai Nortye (ANL) Current Deferred Revenue (2024 - 2025)
Adlai Nortye (ANL) posted quarterly Current Deferred Revenue of $5.0 million for Q4 2024, little changed year-over-year from $5.0 million in Q1 2024, and little changed quarter-over-quarter from $5.0 million in Q2 2024.
Powered by 
Analysis
Adlai Nortye (ANL) Current Deferred Revenue (2024 - 2025) Analysis & Trends
Adlai Nortye (ANL) has reported Current Deferred Revenue for 2 consecutive years, with $5.0 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Current Deferred Revenue changed 0.0% year-over-year to $5.0 million; the TTM figure through Dec 2024 stood at $5.0 million (changed 0.0% YoY), while the FY2024 annual figure was $5.0 million, changed 0.0% from the prior year.
- Current Deferred Revenue was little changed at $5.0 million in Q4 2024 per ANL's latest filing, from $5.0 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $5.0 million in Q4 2023 and bottomed at $5.0 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Adlai Nortye | 500.08 Mn | 268.19 Mn | - |